Andrew received his BSc from the University of Sunderland and his PhD from the University of Newcastle upon Tyne. His research initially focused on genetic determinants of Alzheimer's disease and dementia with Lewy bodies. His postdoctoral studies were spent at the Mayo Clinic in Jacksonville Florida. Andrew worked at the National Institute on Aging at NIH from 2001 to 2025 ending his tenure there as an NIH Distinguished Investigator and Director of the Center for Alzheimer's and Related Dementias. Andrew is a leader of the Global Parkinson’s Genetics Program.
Andrew has published more than 750 articles on a wide variety of topics. He works on the genetic basis of neurodegenerative disorders. The goal of this research is to identify genetic variability that causes or contributes to disease and to use this knowledge to understand the molecular processes underlying disease.
Andrew is currently a member of numerous scientific advisory and editorials boards. Andrew was awarded the Boehringer Mannheim Research Award in 2005, the NIH Director’s Award in 2008 and again in 2016, and the Annemarie Opprecht Award for Parkinson's disease research in 2008. In 2012 he won the Jay van Andel Award for Outstanding Achievement in Parkinson's Disease Research. In 2017 Andrew was awarded the American Academy of Neurology Movement Disorders Award and an Honorary Doctorate from his alma mater, the University of Sunderland. In 2019 Andrew was awarded the Robert A. Pritzker Prize for Leadership in Parkinson's Research. In 2024, Andrew won the Breakthrough Prize in Life Sciences.
Professional position
- Co-Lead, Global Parkinson's Genetics Program
